Targeted Therapy Improves Mobility in Children with Rare Bone Disorder
Researchers found that burosumab safely corrected phosphate loss and improved mobility in patients with severe fibrous dysplasia CHINA, May 20, 2026 /EINPresswire.com/ -- A phase 2 clinical trial showed burosumab, a targeted antibody therapy, …